Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease

Author(s): Matan B. Abou, Liang Sun, Huafeng Wei*.

Journal Name: Current Alzheimer Research

Volume 17 , Issue 4 , 2020

Become EABM
Become Reviewer


Alzheimer’s Disease (AD), a neurodegenerative disorder with high incidence and mortality, is leading its way to the top of the list of the deadliest diseases without an effective disease-modifying drug. Ca2+ dysregulation, specifically abnormal release of Ca2+ via over activated ryanodine receptor (RyR), has been increasingly considered as an alternative upstream mechanism in AD pathology. Consequently, dantrolene, a RyR antagonist and FDA approved drug to treat malignant hyperthermia and chronic muscle spasms, has been shown to ameliorate memory loss in AD transgenic mice. However, the inefficiency of dantrolene to pass the Blood Brain Barrier (BBB) and penetrate the Central Nervous System needs to be resolved, considering its dose-dependent neuroprotection in AD and other neurodegenerative diseases. In this mini-review, we will discuss the current status of dantrolene neuroprotection in AD treatment and a strategy to maximize its beneficial effects, such as intranasal administration of dantrolene.

Keywords: Alzheimer's disease, dantrolene, treatment, intranasal, calcium, blood brain barrier.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [324 - 328]
Pages: 5
DOI: 10.2174/1567205017666200522204722
Price: $65

Article Metrics

PDF: 6